Who owns Protalix Biotherapeutics Inc?
- Ticker: PLX
- CUSIP Number: 74365a309
Tip: Access positions for across all investors
Analyze quarterly positions in Protalix Biotherapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Protalix Biotherapeutics stock
Who bought or sold Protalix Biotherapeutics Inc this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| GSA Capital Partners | 494k | $622k | -9% | Mar 2024 |
|
| Vanguard Group | 303k | $539k | 8% | Dec 2023 |
|
| Bank of America Corporation | 203k | $362k | 17% | Dec 2023 |
|
| Bank of New York Mellon | 173k | $218k | -3% | Mar 2024 |
|
| Charles Schwab Investment Management | 154k | $194k | 0% | Mar 2024 |
|
| Barclays | 126k | $224k | 170% | Dec 2023 |
|
| Goldman Sachs Group | 105k | $186k | -3% | Dec 2023 |
|
| Susquehanna International | 104k | $131k | -31% | Mar 2024 |
|
| Citadel Advisors | 104k | $185k | -11% | Dec 2023 |
|
| Rhumbline Advisers | 77k | $96k | 4% | Mar 2024 |
|
| UBS Group | 75k | $133k | 102% | Dec 2023 |
|
| OZ Management | 74k | $132k | 0% | Dec 2023 |
|
| Orin Green Financial | 72k | $91k | -10% | Mar 2024 |
|
| Commonwealth Equity Services | 50k | $63k | 0% | Mar 2024 |
|
| New York State Common Retirement Fund | 46k | $58k | 1% | Mar 2024 |
|
| Two Sigma Securities | 45k | $79k | 100% | Dec 2023 |
|
| Jpmorgan Chase & Co | 44k | $78k | 0% | Dec 2023 |
|
| Hsbc Holdings | 40k | $71k | 0% | Dec 2023 |
|
| Franklin Resources | 34k | $60k | 100% | Dec 2023 |
|
| American International | 33k | $59k | 0% | Dec 2023 |
|
| Wolverine Trading | 32k | $57k | 100% | Dec 2023 |
|
| Jane Street | 29k | $51k | 100% | Dec 2023 |
|
| Capital Performance Advisors | 26k | $33k | 1% | Mar 2024 |
|
| Alliancebernstein | 23k | $42k | 0% | Dec 2023 |
|
| Wells Fargo & Company | 23k | $29k | 17% | Mar 2024 |
|
| Royal Bank of Canada | 22k | $40k | 96% | Dec 2023 |
|
| SG Americas Securities | 22k | $27k | -38% | Mar 2024 |
|
| Two Sigma Investments | 20k | $35k | -59% | Dec 2023 |
|
| T. Rowe Price Associates | 16k | $29k | 0% | Dec 2023 |
|
| Lido Advisors | 16k | $28k | -2% | Dec 2023 |
|
| Citigroup | 13k | $16k | 10% | Mar 2024 |
|
| ProShare Advisors | 12k | $15k | 100% | Mar 2024 |
|
| Altshuler Shaham | 12k | $22k | 0% | Dec 2023 |
|
| Kestra Advisory Services | 12k | $21k | 0% | Dec 2023 |
|
| Harbour Investment Management | 10k | $13k | 0% | Mar 2024 |
|
| National Bank Of Canada /fi/ | 6.1k | $11k | -82% | Dec 2023 |
|
| TD Waterhouse Canada | 6.0k | $10k | 0% | Dec 2023 |
|
| Legal & General Group | 5.4k | $9.5k | 0% | Dec 2023 |
|
| Summit Investment Advisors | 4.6k | $8.3k | 0% | Dec 2023 |
|
| Advisor Group Holdings | 2.1k | $3.7k | -5% | Dec 2023 |
|
| Amalgamated Bank | 1.9k | $2.0k | -61% | Mar 2024 |
|
| Highlander Capital Management | 610.00 | $1.1k | 0% | Dec 2023 |
|
| Simplex Trading | 459.00 | $0 | 100% | Mar 2024 |
|
| Nelson, Van Denburg & Campbell Wealth Management | 9.00 | $10.999800 | 100% | Mar 2024 |
|
| CWM | 6.00 | $0 | 100% | Mar 2024 |
|
Who sold out of Protalix Biotherapeutics?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Denali Advisors | Dec 2023 | 95k | $169k |
| Connor, Clark & Lunn Investment Management | Dec 2023 | 71k | $126k |
| Bailard | Dec 2023 | 68k | $121k |
| State of Wyoming | Sep 2023 | 41k | $69k |
| Florida State Board of Administration | Dec 2023 | 17k | $31k |
| Virtu Financial | Sep 2023 | 11k | $19k |
| Advisory Services Network | Dec 2023 | 100.00 | $178.000000 |
| Pnc Financial Services | Dec 2023 | 19.00 | $34.000500 |